Dr. Matthew P. Deek, MD | New Brunswick ...

Dr. Matthew P Deek, MD

Claim this profile

Rutgers Cancer Institute of New Jersey

Studies Skin Cancer
Studies Metastases
6 reported clinical trials
12 drugs studied

Area of expertise

1Skin Cancer
Matthew P Deek, MD has run 2 trials for Skin Cancer. Some of their research focus areas include:
Stage I
Stage II
Stage IV
2Metastases
Matthew P Deek, MD has run 1 trial for Metastases. Some of their research focus areas include:
Stage IV

Affiliated Hospitals

Image of trial facility.
Rutgers Cancer Institute Of New Jersey
Image of trial facility.
RWJBarnabas Health - Robert Wood Johnson University Hospital

Clinical Trials Matthew P Deek, MD is currently running

Image of trial facility.

Triapine + Targeted Radiation

for Neuroendocrine Cancer

This phase II trial compares the effect of adding triapine to lutetium Lu 177 dotatate versus lutetium Lu 177 dotatate alone (standard therapy) in shrinking tumors or slowing tumor growth in patients with neuroendocrine tumors that have spread from where they first started (primary site) to other places in the body (metastatic). Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for deoxyribonucleic acid synthesis and cell growth. Lutetium Lu 177 dotatate is a radioactive drug. It binds to a protein called somatostatin receptor, which is found on some neuroendocrine tumor cells. Lutetium Lu 177 dotatate builds up in these cells and gives off radiation that may kill them. It is a type of radioconjugate and a type of somatostatin analog. Giving triapine in combination with lutetium Lu 177 dotatate may be more effective at shrinking tumors or slowing tumor growth in patients with metastatic neuroendocrine tumors than the standard therapy of lutetium Lu 177 dotatate alone.
Recruiting1 award Phase 2
Image of trial facility.

High-Dose Radiation

for Bone Metastases Pain

The investigators hypothesize that with dose escalation to 40-50 Gy in ten fractions, the complete pain response rate at one month can be increased to 40-50% in painful non-spinal bone metastases. Additionally, the investigators hypothesize that utilizing a fractionation scheme with an escalated biologically equivalent dose (BED) will result in a higher proportion of participants responding to treatment, and will also lead to more durable responses. Furthermore, the investigators hypothesize that with dose escalation to 40-50 Gy in ten fractions, the complete pain response rate at one month can be increased to 35-45% in painful non-bone metastases
Recruiting1 award Phase 211 criteria

More about Matthew P Deek, MD

Clinical Trial Related1 year of experience running clinical trials · Led 6 trials as a Principal Investigator · 4 Active Clinical Trials
Treatments Matthew P Deek, MD has experience with
  • EXTERNAL BEAM RADIATION
  • AN0025
  • Capecitabine
  • Fluorouracil
  • Intensity-Modulated Radiation Therapy
  • Mitomycin

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Matthew P Deek, MD specialize in?
Matthew P Deek, MD focuses on Skin Cancer and Metastases. In particular, much of their work with Skin Cancer has involved Stage I patients, or patients who are Stage II.
Is Matthew P Deek, MD currently recruiting for clinical trials?
Yes, Matthew P Deek, MD is currently recruiting for 4 clinical trials in New Brunswick New Jersey. If you're interested in participating, you should apply.
Are there any treatments that Matthew P Deek, MD has studied deeply?
Yes, Matthew P Deek, MD has studied treatments such as EXTERNAL BEAM RADIATION, AN0025, Capecitabine.
What is the best way to schedule an appointment with Matthew P Deek, MD?
Apply for one of the trials that Matthew P Deek, MD is conducting.
What is the office address of Matthew P Deek, MD?
The office of Matthew P Deek, MD is located at: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey 08903 United States. This is the address for their practice at the Rutgers Cancer Institute of New Jersey.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security